Rein Therapeutics
RNTX
52 hedge funds and large institutions have $48M invested in Rein Therapeutics in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 2 closing their positions.
1,100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 2
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
343% more capital invested
Capital invested by funds: $10.8M → $48M (+$37.1M)
73% more funds holding
Funds holding: 30 → 52 (+22)
0.58% more ownership
Funds ownership: 1.28% → 1.86% (+0.58%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
+$15.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$9.02M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.5M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.8M |
| 5 |
Renaissance Technologies
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$94.8K |
| 2 |
Goldman Sachs
New York
|
-$35K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$6.07K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.71K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
51
Valeo Financial Advisors
Carmel,
Indiana
| $1K | +$1.71K | +50 | New |
|
|
MIH
52
Meitav Investment House
Bene-Beraq,
Israel
| $16 | +$18.8K | +550 | New |
|
|
53
Goldman Sachs
New York
| – | -$35K | -1,660 | Closed |
|
|
54
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -65 | Closed |
|
RNTX Hedge Fund Activity: Q1 2021 in Review
52 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2021, worth a combined $48M — up 343% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RNTX positions and 2 closed out — a net gain of 22 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was Alerce Investment Management, adding an estimated $15.4M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $94.8K.
- 52 institutional investors held Rein Therapeutics (RNTX) as of Q1 2021, up from 30 in Q4 2020.
- Funds reported $48M of Rein Therapeutics stock for Q1 2021, up 343% quarter-over-quarter.
- 24 funds opened new Rein Therapeutics positions in Q1 2021 and 2 closed out, a net change of +22 holders.
- The largest Rein Therapeutics buyer in Q1 2021 was Alerce Investment Management, an estimated $15.4M added.
- The largest Rein Therapeutics seller in Q1 2021 was Qube Research & Technologies (QRT), an estimated $94.8K sold.
Based on aggregated 13F filings for Q1 2021.